Clinical trialEPhase 1Completed
Tumor Necrosis Factor in Patients Undergoing Surgery for Primary Cancer or Metastatic Cancer
An Evaluation of the Tissue Distribution and the Selective Tumor Trafficking of TNF-Bound Colloidal Gold (CYT-6091) Following Intravenous Administration in Subjects With Primary and Metastatic Cancer Undergoing Surgical Resection
- Outcome
- Finished, no results posted
- Phase
- EPhase 1
- Status
- Completed
- Study type
- Interventional
- Start
- December 2006
- Expected end
- August 2009
- Enrollment
- 108 participants
- Sites
- 2
- Primary outcomes
- Tumor tissue and normal tissue distribution of colloidal gold-bound tumor necrosis factor; Comparison of the impact of distribution time and histology on accumulation of treatment particles in tumor vs normal tissues
- Sponsor
- Nih
- Results posted
- No
- Last update
- 2 May 2012
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
RATIONALE: Biological therapies, such as tumor necrosis factor, may stimulate the immune system in different ways and stop tumor cells from growing. Studying tumor necrosis factor in samples of tumor tissue and healthy tissue from patients with cancer in the laboratory may help doctors learn how tumor necrosis factor works in tumor tissue and healthy tissue. PURPOSE: This clinical trial is studying tumor necrosis factor in patients undergoing surgery for primary cancer or metastatic cancer .
Detailed description public domain (ClinicalTrials.gov)
OBJECTIVES: Primary * Determine the tumor tissue and normal tissue distribution of colloidal gold-bound tumor necrosis factor in patients with primary or metastatic cancer undergoing surgery. Secondary * Determine, by histological examination of resected tumor tissue, the acute antitumor effects of this treatment in these patients. * Determine the long-term toxicities of this treatment in these patients. * Determine the response to this treatment in these patients. OUTLINE: This is a cohort study. Patients are stratified according to disease type (colorectal cancer vs hepatocellular cancer vs pancreatic exocrine cancer vs pancreatic endocrine cancer vs breast cancer vs melanoma vs primary adrenal tumors vs renal cell carcinoma). Patients receive colloidal gold-bound tumor necrosis factor IV over 15-30 seconds 12-78 hours prior to surgery. Patients then undergo standard-care surgery. Tumor and normal tissues are removed during surgery for analysis of antitumor effects and tissue distribution of colloidal gold-bound tumor necrosis factor by electron microscopy. After completion of study treatment, patients are followed every 3 months for 1 year, every 4 months for 1 year, and then every 6 months for 1 year. PROJECTED ACCRUAL: A total of 108 patients will be accrued for this study.